Innovative AI, digital health tools, and novel biomarkers are helping advance personalised cardio-oncology care for older breast cancer patients across Europe.

The CARDIOCARE project is proud to announce a significant milestone in its mission to improve cardiovascular care for older breast cancer patients at risk of cardiotoxicity associated with cancer treatment. As highlighted in a recent press release by the European Society of Cardiology (ESC), CARDIOCARE has achieved important scientific and technological advances that are helping shape the future of personalised cardio-oncology care.

Over the past five years, the CARDIOCARE consortium has brought together leading researchers, clinicians, and technology experts from across Europe to address one of the growing challenges in cancer survivorship: protecting heart health during and after cancer treatment.

Among the project’s key achievements are:

• The creation of a unique multimodal dataset integrating clinical, imaging, omics, lifestyle, psychological, and sensor-based data from more than 2,200 breast cancer patients.
• The development and deployment of innovative digital health applications, including ePsycHeart and eHealthHeart, designed to support patient wellbeing, self-management, and quality of life.
• The design of advanced artificial intelligence models capable of predicting cardiotoxicity risk, frailty, quality-of-life deterioration, and cardiac abnormalities.
• The identification of promising biomarkers, including microbiome-related indicators, that may contribute to earlier detection and more precise risk stratification.

These advances represent a major step toward personalised, preventive, and patient-centred healthcare for older patients with breast cancer, a population that has historically been underrepresented in clinical research.

As the project enters its final phase, CARDIOCARE continues to focus on translating research findings into practical tools and evidence-based approaches that can support healthcare professionals in delivering safer and more effective cancer care.

The consortium would like to thank all participating patients, healthcare professionals, researchers, and partner organisations whose contributions have made these achievements possible.